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Exposure to 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) causes loss of dopaminergic neurons in humans, primates and mice. 
Exposure of sagittal slices of mouse brain to MPTP (100 pM) caused inhibition of mitochondrial NADH-dehydrogenase activity. Leakage of 
lactate dehydrogenase from the slice into the medium was observed following incubation of slices with 1 nM MPTP. Neurotoxicity induced 
by MPTP was prevented by prior exposure of the slices to the dopamine uptake inhibitor GBR 12935. Deprenyl and pargyline (inhibitors of 
monoamine oxidase), also protected the slices from MPTP-induced toxicity. However, both pargyline and deprenyl also inhibited cytochrome 
P-450 mediated aminopyrine N-demethylase activity in brain slices. Pargyline, when administered in vivo to mice, decreased brain cytochrome 
P-450 levels ignificantly. Other cytochrome P-450 inhibitors, namely, piperonyl butoxide and SKF 525A were found to offer protection against 
MPTP induced neurotoxicity in slices without affecting monoamine oxidase activity. MPTP toxicity was potentiated significantly in brain slices 
prepared from mice pretreated with phenobarbital, ninducer of cytochrome P-450. The present study suggests the possible involvement of
cytochrome P-450 in MPTP-induced neurotoxicity, in vitro, in brain slices. 
INTRODUCTION 
MPTP (1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine), a 
by-product of meperidine synthesis causes Parkinson's 
disease-like symptoms in humans 9 and primates 3. In 
mouse, MPTP causes selective destruction of the dopa- 
minergic neurons 11. MPTP per se is not neurotoxic, but 
is metabol ized by monoamine oxidase (MAO)  5'16 to the 
toxic compound N-methyl phenylpyridine (MPP+), 
which is selectively taken up into the dopaminergic 
neurons, leading to cell death ~8. MPP ÷ exerts its toxic 
effects by inhibiting mitochondrial respiration. Oxidative 
metabol ism of NAD- l inked substrates is inhibited by 
MPP ÷ within the mitochondria, due to inhibition of 
NADH-dehydrogenase (NADH-DH)  19. Prior adminis- 
tration of monoamine oxidase (MAO)  inhibitors (name- 
ly, pargyline and deprenyl) prevents dopaminergic neu- 
rotoxicity of MPTP ~2,~5. MPTP-induced toxicity is also 
inhibited by administration of dopamine uptake 
blockers 25. 
Microsomal cytochrome P-450 (P-450) and flavin-con- 
taining mono-oxygenase are known to play a role in the 
detoxification of MPTP 4'6. Recent reports have indicated 
the presence of substantial amounts of cytochrome P-450 
and NADPH cytochrome P-450 reductase in brain 1' 
20,21,23, and their predominant localization in the mid- 
brain region. The present study was undertaken to 
examine the possible role of brain cytochrome P-450 and 
associated mono-oxygenase activity in MPTP-induced 
neurotoxicity, in vitro, using mouse brain slices. 
MATERIALS AND METHODS 
Male Swiss Albino mice (3 months old) from the Institute's 
animal house were used for the experiments. Animals had free 
access to pelleted diet (Hindustan Lever, Bombay, India) and 
water. Mice were decapitated and the brain was quickly removed 
and cut into sagittal slices (500 #m thickness) manually. Slices were 
incubated in artificial cerebrospinal fluid (CSF) 1° at 37 0(2 in an 
atmosphere of oxygen with and without MPTP. After incubation for 
specific time periods, slices were removed, rinsed and homogenized 
in 0.32 M sucrose. The homogenate was centrifuged at 1000 g for 
10 min and the supernatant was used for the assay of NADH-DH TM. 
Brain homogenate was freeze-thawed in liquid nitrogen before assay 
of the enzyme activity. The homogenate containing 90-120 gg of 
protein was added to a spectrophotometric cuvette, containing 0.28 
mM NADH in phosphate buffer (0.05 M, pH 7.6) and 0.25 M 
sucrose. The total volume was 1 ml. Rate of change of absorbance 
at 340 nm was monitored at 25 *(2. Leakage of cytoplasmic lactate 
dehydrogenase (LDH) from the slices into the medium was also 
measured as an indicator of cell damage t3. After the incubation was 
complete, the artificial CSF was filtered through Whatman No. 1 
filter paper and used for the assay of LDH. To 1 ml of phosphate 
buffer (50 mM, pH 7.4) containing 0.65 mM pyruvate and 11.3 mM 
NADH, 20 /~1 of artificial CSF Was added and the change in 
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absorbance was monitored at 340 nm. 
Studies using inhibitors of P-450 and MAO were carried out by 
preincubating the slices at 37 °C with deprenyl, pargyline, piperonyl 
butoxide, SKF 525A or GBR 12935 for 30 min. MPTP (10 nM) was 
then added and the slices were incubated for a further period of 1 
h. 
Induction of mouse brain P-450 was carried out by administration 
of phenobarbital in drinking water (0.1%) for 10 days, followed by 
i.p. injections of phenobarbital (80 mg/kg b. wt.) every day for 10 
days. Control animals received vehicle alone. Animals (phenobar- 
bital-treated and control) were sacrificed 24 h after the last 
injection. Brain slices were prepared immediately from both 
groups of animals and incubated with 0.01, 0.05 and 1 nM MPTP 
at 37 °C for 1 h, and the slices were processed as described earlier. 
NADH-DH was assayed in the homogenate and LDH activity was 
measured in the artificial CSE The activity of MAO was determined 
in the homogenate using kynuramine as substrate TM. Brain slice 
homogenate was added to 1 ml of pyrophosphate buffer (pH 8.6) 
and 0.1 mM kynuramine, and incubated for 30 min at 37 °C. The 
reaction was stopped by the addition of 0.1 ml of 5% trichloroacetic 
acid and centrifuged. The supernatant was collected and 1 ml of 
sodium hydroxide (1 M) was added and the fluorescence was 
monitored using an excitation wavelength of 320 nm and emission 
wavelength 385 nm. 4-Hydroxyquinoline was used as standard. 
Aminopyrine demethylase activity was assayed as described 
earlier 2° with slight modifications. Brain slice homogenate contain- 
ing 10-30 #g protein, was incubated in 0.05 M "Iris buffer (pH 7.5) 
containing, magnesium chloride (20 raM), aminopyrine (1.8 mM), 
in a total volume of 1 ml. After preincubation for 3 min, the reaction 
was initiated by the addition of NADPH to a final concentration f 
3 mM. The incubation was continued for 10 min and then the 
reaction was stopped by the addition of 0.5 ml of trichloroacetic a id 
(10% w/v). The contents were centrifuged and the formaldehyde 
formed was estimated in the supernatant using NASH reagent 2°. 
Blanks containing no NADPH were run simultaneously. 
Pargyline (15 mg/kg b. wt.) was administered i.p. to mice. 
Animals were sacrificed 4 h later and brain microsomes were 
prepared from control and pargyline-treated animals and total P-450 
concentration was estimated from the reduced carbon monoxide 
spectra 22. Protein was estimated by the dye-binding method 2.Data 
were analyzed by one-way analysis of variance and statistical 
significance was determined using Duncan's test. Student's t-test was 
also used where appropriate. 
RESULTS 
Mouse brain slices were incubated with various con- 
centrations of MPTP at 37 °C for 1 h. Significant 
inhibition of NADH-DH (14%) was observed upon 
incubation of slices with very low concentration f MPTP 
(100 pM). The inhibition of NADH-DH increased with 
increasing concentration of MPTP (Fig. 1). When the 
slices were incubated with 1 mM MPTP 64% inhibition 
of NADH-DH was observed. Leakage of LDH from the 
slices into the medium was significantly increased (16%) 
following incubation of the slices with 1 nM MPTP (Fig. 
1). Upon incubation of slices with MPTP (10 nM), 
significant decrease in the activity of NADH-DH was 
observed after 30 min of incubation, while leakage of 
LDH into the medium was observed after 1 h (data not 
shown). 
Dopamine uptake inhibitor GBR 12935 effectively 
protected against MPTP-induced inhibition of NADH- 
DH (Fig. 2A) and leakage of LDH from the slice to the 
medium (Fig. 2A'). Preincubation of mouse brain slices 
with deprenyl and pargyline (MAO inhibitors), prior to 
exposure to MPTP (10 nM) resulted in protection against 
MPTP-induced inhibition of NADH-DH (Fig. 2B, C) 
and leakage of LDH (Fig. 2B', C'). Slices were prein- 
cubated with P-450 inhibitors, namely, piperonyl but- 
oxide (Fig. 2D, D') or SKF 525A (Fig. 2E, E') and then 
exposed to MPTP for 1 h, following which NADH-DH 
and LDH activity were measured in the slice and 
medium, respectively. The activities of both enzymes in 
incubations containing MPTP were not significantly 
different from controls containing inhibitors only. In 
control incubations containing inhibitors only, leakage of 
LDH from the slices was observed at higher concentra- 
tion of inhibitors. Therefore, two sets of incubations were 
performed, one set containing various concentrations of 
inhibitors alone and the other set containing the inhibio 
tors and MPTP. 
The effect of the above MAO and P-450 inhibitors on 
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Fig. 1. Effect of varying concentrations of MPTP on NADH-DH 
activity and LDH leakage in mouse brain slices. Sagittal slices of 
mouse brain were incubated in artificial CSF containing varying 
concentrations of MPTP for 1 h at 37 °C. NADH-DH activity was 
measured in the slices, while the leakage of LDH was monitored in 
the medium. Values are expressed as mean + S.E.M. (n = 6-8). 
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Fig. 2. Effect of inhibitors of dopamine uptake, MAO and P-450 on MPTP-induced inhibition of NADH-DH and LDH leakage in slices. Two 
sets of slices were preincubated for 30 min at 37 °C with varying concentrations of GBR 12935 (A, A'), deprenyl (B, B'), pargyline (C, C'), 
piperonyl butoxide (D, D') and SKF 525A (E, E'), following which MPTP (10 nM) was added to one set of slices. Respective controls ((3) 
and MPTP treated slices (Q) were incubated for a further period of 1 h. The activities of NADH-DH (A-E) and LDH (A ' -E ' )  are expressed 
as mean + S.E.M. (n = 6-8). *, Values significantly different from respective controls (P < 0.05). 
O-006 
c-  
"60 '  004 
E 0' 002 
=c 
E 
0 -12 
:3 
13  
B 0 -08 
G 
E 0 04 
"1 
B C L 
, , , , , A ,  I l , , ,  , , , : : ,  , , : , 
0 50 I00 150 0 0"I 05 0 01 0"5 0 1 10 I00 0 1 10 
A I B' Cl  
-le 
I I II I 
0 0.1 0.5 
DEPRENYL ( I..IM ) 
~ E' 
t ~ 
,It. If- 
i i L ;; I 
0 1 10 100 
PIP-BUT (pM) 
I l 1 I A I ~, I 1 i U 110 
0 50 100 150 0 0.1 0.5 0 1 
GBR 12935 (nM) PARGYLINE (~ M ) SI'(F-525A (I.iM) 
Fig. 3. The effect of various inhibitors of dopamine uptake, MAO and P-450 on MAO activity and P-450 mediated APD activity. Two sets 
of slices were preincubated with varying doses of GBR 12935 (A, A'), deprenyl (B, B'), pargyline (C, C'), piperonyl butoxide (D, D') and 
SKF 525A (E, E'), after which MPTP (10 nM) was added to one set of slices, as indicated in Fig. 2. MAO (A-E) and P-450 mediated APD 
activity (A ' -E ' )  were monitored in the slices containing inhibitor alone ((3) and slices containing both inhibitor and MPTP (O). Values are 
mean + S,E.M. (n = 4-6). *, Values significantly different (P < 0.05) from controls which did not contain any inhibitor. 
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Fig. 4. Effect of phenobarbital pretreatment on MPTP-induced 
inhibition of NADH-DH and LDH leakage in brain slices. Brain 
slices were prepared from control (O) and phenobarbital-treated 
(0)  mice and incubated with varying concentration of MPTP for 1 
h at 37 °C. NADH-DH activity was measured in the slice and LDH 
activity was monitored in the medium. Values are expressed as 
mean + S.E.M. (n = 4-6). *, Values significantly different from 
respective controls, which were not treated with MPTP (P < 0.05). 
the activities of both MAD and P-450 mediated mono- 
oxygenase activity (namely, APD), in brain slices, was 
also investigated (Fig. 3). Both deprenyl and pargyline 
effectively inhibited MAD activity in brain slices in a 
dose-dependent manner (Fig. 3B, C), while GBR 12935 
had no effect (Fig. 3A). However, pargyline and de- 
prenyl also inhibited P-450-mediated APD activity sig- 
nificantly, in the slices (Fig. 3B', C', respectively). 
Piperonyl butoxide and SKF 525A, selectively inhibited 
APD activity (Fig. 3D, E); activity of MAD was not 
significantly different from controls (Fig. 3D', E'). MPTP 
alone did not have any significant effect on the activity of 
either MAD or APD activity (Fig. 3). 
In order to study the effect of pargyline in vivo, in the 
whole animal, pargyline (15 mg/kg) was administered i.p. 
to 4 mice and the animals were sacrificed 4 h later. Brain 
microsomes were prepared from control animals (treated 
with vehicle alone) and pargyline-treated animals and the 
total P-450 levels were measured 22. Brain microsomal 
P-450 levels were decreased by 29% in pargyline treated 
animals. The total brain P-450 levels in control animals 
was 0.07 + 0.005 nmol/mg protein, while in pargyline 
treated animals it was 0.05 + 0.006 nmol/mg microsomal 
protein (data not shown). Pargyline also inhibited mito- 
chondrial MAD activity by 60%. The mitochondriai 
MAD activity was 8.98 + 1.0 nmol product formed/ 
min/mg protein in control animals. 
Involvement of P-450 in MPTP-induced neurotoxicity 
was further examined by studying the effect of induction 
of brain P-450 levels on MPTP-induced inhibition of 
NADH-DH and LDH leakage in brain slices. Brain slices 
were prepared from mice treated with phenobarbital nd 
from control animals, that received vehicle alone. The 
slices were exposed to various concentrations of MPTP 
(0.01-1 nM), and the activity of NADH-DH was assayed 
in the slice and LDH activity was measured in the 
medium. Inhibition of NADH-DH and LDH leakage 
(Fig. 4) was observed following exposure of brain slices 
prepared from phenobarbital treated animals to 0.05 nM 
MPTP. In brain slices from control animals, similar 
toxicity was observed only after exposure to 1 nM MPTP. 
Pretreatment with phenobarbital had no effect on brain 
MAD activity, while P-450 mediated APD activity was 
induced two-fold (data not shown). 
DISCUSSION 
The present study demonstrates the neurotoxicity of 
MPTP, in vitro, in mouse brain slices at a very low 
concentration, amely, 0.1 nM. The concentration of 
MPTP in mouse brain following in vivo administration of
neurotoxic dose of MPTP has been reported to be 300 
tM 16. The concentration of MPTP (500 tiM) used in 
earlier in vitro studies has been much higher 19, than that 
used in the present study (0.1 nM). 
The inhibition of NADH-DH by MPTP preceded the 
leakage of LDH from the slices (Fig. 1). Only after 
incubation of mouse brain slices at much higher concen- 
tration of MPTP (10 tM-1  mM), inhibition of lysosomal 
enzymes (N-acetyl glucosaminidase and acid phospha- 
tase) and isocitrate dehydrogenase (mitochondrial en- 
zyme) was observed (data not shown). This is in 
agreement with earlier studies wherein selective inhibi- 
tion of NADH-DH was observed 19. 
Administration of pargyline or deprenyl (MAD inhib- 
itors) is known to protect he dopaminergic neurons from 
MPTP-induced damage 7J2'15. Similar effect is seen, in 
vitro in the brain slices (Fig. 2). However, exposure of 
brain slices to pargyline or deprenyl also resulted in 
significant decrease of P-450 mediated APD activity (Fig. 
3). As P-450 is known to exist in multiple forms in the 
brain, measurement of APD activity alone may not 
reflect he status of the total brain P-450 in the brain slice. 
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However, it was not possible in our hands to measure 
total P-450 levels in the slice, due to the small sample 
size. Therefore, the effect of pargyline on brain P-450 in 
vivo was also examined. Administration of pargyline to 
mice (15 mg/kg, the dose and route known to protect 
against MPTP toxicity 12) also resulted in significant 
decrease of cerebral P-450 levels (30%). The inhibition of 
P-450 by deprenyl is of special interest, as it has been 
recommended for therapeutic use in Parkinson's dis- 
ease 26. The inhibition of the major drug metabolizing 
enzyme, namely, P-450 in the brain by MAO inhibitors 
would have a profound effect on the pharmacological 
modulation of other drugs given in combination with 
MAO inhibitors. 
The effect of other well-characterised inhibitors of 
P-450 on MPTP-toxicity was examined. Both SKF 525A 
and piperonyl butoxide effectively prevented MPTP- 
induced damage to the slice (Fig. 2). Higher doses of 
piperonyl butoxide are required for the inhibition of 
P-45024, as compared to the doses required for the 
inhibition of MAO by pargyline 12. Therefore, the con- 
centration of piperonyl butoxide (1 #M) used in the 
present study was higher than that of pargyline (0.1/zM). 
Both SKF 525A and piperonyl butoxide selectively 
inhibited P-450 mediated APD activity, but had no effect 
on MAO activity in the slices. Earlier studies have 
demonstrated that SKF 525A is not a competitive ligand 
for the mazindol sensitive dopamine transporter 17. Thus, 
the protective effect of SKF 525A is not exerted by 
inhibition of MAO or inhibition of dopamine uptake. 
Similar studies were carried out with MPP +, the 
neurotoxic metabolite of MPTP and it was found that 
MPP + inhibited NADH-DH activity only at significantly 
higher concentration (10 #M, million fold higher) than 
the concentration of MPTP (100 pM) necessary to 
produce similar toxicity. Earlier in vitro studies with 
MPP ÷ have also demonstrated that MPP ÷ was toxic at 
very high concentrations 19.Therefore, it was difficult to 
compare the relative effects of various P-450 and MAO 
inhibitors on MPTP and MPP ÷ induced toxicity. 
The protection offered by P-450 inhibitors against 
MPTP-induced toxicity was selective. Metarypone, a 
selective inhibitor of P-450c,d 8, did not offer any protec- 
tion against MPTP-mediated toxicity (data not shown). It 
is interesting to note that the predominant form of P-450 
in the mouse brain is P-450b, e (which is inducible by 
phenobarbital); P-450c, a has been found to be virtually 
absent 2°. The potentiation of MPTP-toxicity by pheno- 
barbital treatment thus suggests the involvement of P-450 
in MPTP-induced toxicity (Fig. 4). 
The present study demonstrates the possible involve- 
ment of P-450 in MPTP toxicity. However, the actual 
mechanism of P-450 action is yet unclear. Further, the 
extrapolation of the in vitro results to actual in vivo 
situation also needs to be determined. Regardless of the 
mechanism of action, inhibition of cytochrome P-450 
levels in the brain may be of importance in preventing 
MPTP-induced damage to the brain. 
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